Table 2 Demographic and clinical data of JIA patient development and evaluation groups.
Development group | Evaluation group | |
|---|---|---|
Number of patients (M/F) | 18 (4/14) | 29 (8/21) |
Age (years) at inclusions (± SD) | 10.9 (± 4.3) | 10.1 (± 3.24) |
Disease duration at study entry (years, ± SD) | 4.6 (± 4.1) | 4.7 (± 3.25) |
Number of JIA patients (M/F) | 16 (3/13) | 25 (7/18) |
JIA category | ||
Oligoarthritis | 7 | 13 |
Polyarthritis | 6 | 8 |
Psoriasis | 1 | 2 |
Enthesitis-related arthritis | 2 | 2 |
Patients with uveitis: n (M/F) | 9 (1/8) | 16 (3/13) |
JIA associated Uveitis (M/F) | 7 (0/7) | 12 (2/10) |
Chronic non-infectious uveitis (M/F) | 2 (1/1) | 4 (1/3) |
ANA positivity (%) | 11 (61%) | 21 (72%) |
Concomitant treatment with MTX (number) | 86% (13) | 58% (17) |
Duration (months) of concomitant MTX (± SD) | 32.2 (± 29.4) | 40.6 (± 32.4) |
Duration (months) of Adalimumab (± SD) | 29.3 (± 32.7) | 26.7 (± 28.2) |
JIA inactive disease during drug administration (number/JIA patients) | 69% (11/16) | 64% (16/25) |
Uveitis inactive disease during drug administration (number/uveitis patients) | 78% (7/9) | 87.5% (14/16a) |
For JIA patients | ||
JADAS-10 (± SD) at Adalimumab introduction | 13.7 (± 5.03) | 14.8 (± 9.45) |
JADAS-10 at ADAbs testing | 2.7 (± 3.78) | 2.8 (± 3.24) |
